Live Breaking News & Updates on Human Drug Research

Stay updated with breaking news from Human drug research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Immutep's anti-cancer clinical trials advancing rapidly – here are next catalysts for investors

Immutep's anti-cancer clinical trials advancing rapidly – here are next catalysts for investors
theaustralian.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theaustralian.com.au Daily Mail and Mail on Sunday newspapers.

United States , Marc Voigt , Byeddy Sunarto , Merck Co , Centre For Human Drug Research , European Medicines Agency , American Society Of Clinical Oncology , Frankfurt Institute Of Clinical Cancer Research , American Society , Clinical Oncology , Eftilagimod Alpha , Frankfurt Institute , Clinical Cancer Research , Human Drug Research ,

Hot Money Monday: Expert says buying stock at 52-week high is better than 'buy low - sell high' strategy

Hot Money Monday: Expert says buying stock at 52-week high is better than 'buy low - sell high' strategy
stockhead.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stockhead.com.au Daily Mail and Mail on Sunday newspapers.

Nifty Copper Mine , Western Australia , Saudi Arabia , Puerto Las Losas , Mark Minervini , Admiralty Minerals Chile , Centre For Human Drug Research , Macmahon Holdings , Energy Fuels , Mayfield Group , Decmil Group , Bisalloy Steel Group , Axiom Properties , Vinyl Group , Galilee Energy , Saudi Ministry Of Investment , Stock Market Wizard , Simple Moving , Moving Averages , Moving Average , Mariposa Iron Ore Project , Resource Estimate , Relative Strength , Relative Strength Index , Human Drug Research , Middle East ,

Algernon NeuroScience and the Centre for Human Drug

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT:. ....

Noord Holland , United Kingdom , British Columbia , Christopherj Moreau , Rick Strassman , Algernon Pharmaceuticals Inc , Constraint Induced Movement Therapy , Algernon Pharmaceuticals , Centre For Human Drug Research , Seyltx Inc , Interdisciplinary Conference On Psychedelic Research , Company Phase , Algernon Neuroscience , Human Drug Research , Interdisciplinary Conference , Psychedelic Research , Katelijne Van , Spirit Molecule , Brain Derived Neurotrophic Factor , Constraint Induced Movement , Stroke Study , Canadian Stock Exchange Agn Cn , Algernon Pharmaceuticals Inc , Phase 1 , Algernon Neuroscience ,

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

New South Wales , Matthijs Moerland , Chris Basta , Pediatric Research , Immutep Limited , Centre For Human Drug Research , Corporate Communications , Appoints Leading Research Institute , Conduct First In Human Phasei Study , Human Drug Research , Chief Scientific Officer , Director Immunology , Principal Investigator , Lymphocyte Activation , Investor Relations , Curr Opin , Res Ther , Relapsing Remitting Multiple Sclerosis ,

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it plans to move forward with its intravenous formulation of its AP-188 (“N,N-Dimethyltryptamine” or “DMT”) stroke research program as its lead asset, after having sold its Ifenprodil research program for USD $2M cash and a 20% common share ....

British Columbia , United Kingdom , Christopherj Moreau , Company Or Algernon , Algernon Pharmaceuticals , Algernon Pharmaceuticals Inc , Centre For Human Drug Research , Company Phase , Algernon Neuroscience , Stroke Study , Human Drug Research , Algernon Pharmaceuticals Inc , Clinical Trial Design , Research Program , Algernon Neuroscience ,